NKGN
NKGen Biotech, Inc. Common Stock·Healthcare
0.06
0.000%(−0.00)
Market ClosedLast Updated: — ET
52W L: $0.0052W H: $0.77
NKGN NEWS
globenewswire.com
2d ago
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.
globenewswire.com
Mar 23
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.
globenewswire.com
Mar 10
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (“AD/PD™ 2026”), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually.
defenseworld.net
Feb 8
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
Profitability This table compares NKGen Biotech and SQZ Biotechnologies' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% SQZ Biotechnologies -369.96% -119.83% -59.90% Valuation and Earnings This table compares NKGen Biotech and SQZ Biotechnologies"s revenue, earnings per share and valuation. Gross Revenue
defenseworld.net
Feb 2
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
Profitability This table compares SQZ Biotechnologies and NKGen Biotech's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% NKGen Biotech N/A N/A -479.36% Valuation and Earnings This table compares SQZ Biotechnologies and NKGen Biotech"s top-line revenue, earnings per share (EPS) and valuation.
globenewswire.com
Jan 22
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
Dr. Miller's appointment further enhances NKGen's scientific and clinical advisory capabilities as the Company advances its research in Alzheimer's and other related neurodegenerative diseases Dr. Miller's appointment further enhances NKGen's scientific and clinical advisory capabilities as the Company advances its research in Alzheimer's and other related neurodegenerative diseases
